Back to top
more

MiMedx Group (MDXG)

(Real Time Quote from BATS)

$6.29 USD

6.29
312,466

+0.05 (0.72%)

Updated Apr 26, 2024 01:47 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

MiMedx Group, Inc [MDXG]

Reports for Purchase

Showing records 1 - 20 ( 22 total )

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 1

02/29/2024

Company Report

Pages: 7

Positioning for Long Term Growth; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 2

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for MDXG 112223

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 3

10/31/2023

Company Report

Pages: 8

Profitability Achieved; Multiple Drivers to Sustain Long-Term Growth; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 4

08/02/2023

Company Report

Pages: 7

Wound Surgical Revenues Growth Ensures Profitability in 2H; New $11 PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 5

06/21/2023

Company Report

Pages: 6

Strategic Realignment to Focus on Wound Surgical Business; Expect Positive EPS in 2H23; Lower $8 PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 6

05/03/2023

Company Report

Pages: 6

Strong start to 2023; New $9.50 PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 7

03/02/2023

Company Report

Pages: 7

Achieve Profitability in 2023; Long-Term Thesis Intact; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 8

01/10/2023

Daily Note

Pages: 3

Awaiting CMS Town Hall for Clarity on Reimbursement; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 5.00

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 9

11/03/2022

Company Report

Pages: 7

New CEO Leads with Strategic Initiatives; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 10

09/07/2022

Company Report

Pages: 6

A Softer 3Q22 Expected; CEO Transition Initiated; PT Adjusted to $8; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 11

08/04/2022

Company Report

Pages: 7

Multiple Launches Upcoming in 3Q22; KOA Study on Track; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 12

05/05/2022

Company Report

Pages: 7

Growth in Core Business Driving 2022 Revenues; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 13

03/01/2022

Company Report

Pages: 7

Japanese Launch Upcoming; KOA Pivotal Study to Start in 2H22; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 14

01/20/2022

Company Report

Pages: 6

Outlook for 2022 and Beyond Appears Positive; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 15

12/08/2021

Company Report

Pages: 7

Focus Remains on KOA Indication; Japanese and Product Launches to Drive Growth; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 16

11/04/2021

Company Report

Pages: 7

Core Business Remains Strong; Investor Day in December; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 17

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for MDXG

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 18

09/14/2021

Company Report

Pages: 7

mdHACM Fails PF; Hope For KOA Continues; Lower PT to $8.50; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 19

08/06/2021

Company Report

Pages: 7

Awaiting Major Data Readouts; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: MiMedx Group, Inc

Industry: Medical - Biomedical and Genetics

Record: 20

06/09/2021

Daily Note

Pages: 3

Approval in Japan to Accelerate EpiFix Global Expansion

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party